TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease ( Hughes AJ et al. 2001)~* Patients with motor fluctuations~* Chronic Insomnia disorder criteria according to the criteria of DMS- V ( American Psychiatric Association, 2013) and insomnia severity index \> 15~* Able to use independently the device required for treatment by apomorphine~* Collection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) .~* Affiliate to social security or beneficiary of such a regime~Exclusion Criteria:~* Atypical Parkinsonian Syndromes~* Parkinson's disease with dementia (Montreal Cognitive Assessment (MoCA) \<25/30 (NASREDDINE and al., 2012))~  * Parkinson's disease with hallucinations~ * Parkinson's disease with impulse Control disorder (ICD)~ * Parkinson's disease already treated with APOMORPHINE pump or justifying the use of the pump continuously day and night~ * Another obvious severe disease explaining insomnia~ * Exclusion for monitoring difficulties (mutation, insufficient motivation, priority associated pathology in care)~ * Patient unwilling to accept a pump~ * Patient not accepting polysomnography and multiple sleep latency test~ * Patient with health problems or a skin disease precluding continuous subcutaneous infusion~ * Female parturient or nursing~ * Cardiac dysrhythmia precluding treatment with domperidone or apomorphine (increased QTc ≥ 440 ms in men, QTc ≥ 450 ms in women)~ * Treatments forbidden in association with apomorphine such as:~    * antiemetic neuroleptics~   * Tetrabenazine~ * Excessive alcohol consumption~ * Contraindications for apomorphine:~    * Hypersensitivity to apomorphine or one of the excipients~   * Respiratory Depression~   * Hepatic impairment~   * Intellectual Disability~   * Dementia

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Apomorphine (5 mg/ml) (Type: ACTIVE_COMPARATOR): Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
- Physiologic serum (Type: PLACEBO_COMPARATOR): Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of HL-085 in NRAS Mutant Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed unresectable Stage III or Stage IV melanoma according to AJCC (Version 7, 2010).~2. Subjects must have NRAS mutation in melanoma.~3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment.~4. ECOG performance status of 0-1.~5. Life expectancy ≥ 3 months.~6. Ability to take the medicine orally.~7. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Prior therapy with a MEK-inhibitor~2. Patients with known hypersensitivity to study drug ingredients or their analogues.~3. Active central nervous system (CNS) lesion.~4. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome.~5. Subjects with bleeding symptoms at Grade 3 (NCI-CTCAE v4.03) within 4 weeks prior to starting study treatment.~6. Uncontrolled concomitant diseases or infectious diseases.~7. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial detachment (RPED) , et al.).~8. History of HIV,HCV,HBV infection.~9. Interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded.~10. Serum HCG test is positive.~11. Other conditions that influence the results and increase the risk of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HL-085 (Type: EXPERIMENTAL): HL-085 will be administered as BID with specified dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Losartan in the Treatment of NAFLD in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) \> 85th% for age and gender~* History of definite or borderline nonalcoholic steatohepatitis (NASH) diagnosed by liver biopsy using NASH Clinical Research Network (CRN) criteria~* At least 2 months of attempted lifestyle changes after liver biopsy~* Current ALT ≥ 3 times normal (69 U/L for girls, 78 U/L for boys) at enrollment~* Glomerular filtration rate (GRF) \> 90~* Weight ≥ 62.5 kg~Exclusion Criteria:~* Other chronic illness requiring daily medication (except medications for mild mental illness, acid reflux, allergies, stable attention deficit hyperactivity disorder (ADHD), or asthma)~* Supplement or anti-oxidant therapy within past 2 weeks~* Renal insufficiency~* Cirrhosis and liver synthetic dysfunction (International Normalized Ratio ≥ 1.5)~* History of hypotension~* Diabetes (or fasting glucose \> 125 mg/dL)~* Acute illness within past 2 weeks prior to enrollment (fever \> 100.4ºF)~* Pregnancy

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Losartan then Placebo (Type: EXPERIMENTAL): 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
- Sugar pill (Type: EXPERIMENTAL): placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>18 years old~* Patients with CD was diagnosed clinically according to previously established international criteria \[9\]~* The diagnosis of stricture, fistula and abdominal abscess was confirmed by ultrasound, CT enterography (CTE), and endoscopy. The bowel stricture should mainly cause by inflammation but not fibrosis.~Exclusion Criteria:~* Patients do not macth the inclusion criteria and those who refuse to taking part in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy women~* singleton pregnancy~* caesarean section under regional anaesthesia~* older than 18 years~* written informed consent~Exclusion Criteria:~* emergency caesarean section~* secondary caesarean section due to fetal distress~* comorbidities (cardiovascular, kidney or liver disorder, epilepsy)~* obstetric diseases (hypertension, (pre-)eclampsia)~* uterine malformation (including uterine fibroids)~* bleeding disorder~* known hypersensitivity to carbetocin or oxytocin~* fetal malformation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Short infusion (Type: EXPERIMENTAL): Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
- Bolus application (Type: OTHER): Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Ghrelin Agonist in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy males~Exclusion Criteria:~* Females

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of CPAP Level on V/Q Mismatch in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Born at 27-35 weeks gestational age (GA) by best obstetric estimate, determined by the clinical obstetric team during antepartum admission.~2. Age limits: 24 hours of age - 35 weeks corrected gestational age.~3. On continuous CPAP support between 4-8 cm H2O for greater than 24 hours, as document on the bedside infant flow sheet.~4. Supplemental oxygen requirement, with a fraction of inspired oxygen (FiO2) 0.25 for at least 2 consecutive hours, as documented on the bedside infant flow sheet.~Exclusion Criteria:~1. Congenital anomalies, as determined by the clinical supervising physician.~2. Current or prior air leak syndrome, as determined by the clinical supervising physician.

- Gender: ALL
- Minimum Age: 24 Hours
- Maximum Age: 35 Weeks
- Healthy Volunteers: f

Study Arms:
- Continuous positive airway pressure (CPAP) level changes (Type: EXPERIMENTAL): Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Ankylosing Spondylitis~* Has active disease despite concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) treatment or is intolerant to NSAIDs~Exclusion Criteria:~* Pregnant or lactating females~* Currently receiving or previous use of a Tumor Necrosis Factor (TNF) inhibitor or any biological agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 2 mg (Type: EXPERIMENTAL): None
- Tofacitinib 5 mg (Type: EXPERIMENTAL): None
- Tofacitinib 10 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Treatment with oral anti-diabetic drugs for at least 3 months~* HbA1c: 7.0-11.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy~* Body Mass Index (BMI) less than or equal to 45.0 kg/m2.~Exclusion Criteria:~* Treatment with insulin within the last three months~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have the intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Hospitalized and mechanically ventilated for illness related to SARS-CoV-2~* Confirmed positive SARS-CoV-2 infection by Polymerase chain reaction (PCR)~* individual or surrogate ability to sign informed consent~* negative, urine-based pregnancy test in females~Exclusion Criteria:~* contraindication or intolerance to dornase alfa~* mechanical ventilation expected to be less than 48 hours~* life expectancy less than 24 hours based upon judgement of treating physician~* pregnant~* inability to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled/nebulized dornase alfa (Type: EXPERIMENTAL): Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
- Standard of care (Type: NO_INTERVENTION): Standard of care provided for ARDS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Male Volunteers who are ≥19 years old~* Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and~Exclusion Criteria:~* Clinically significant Medical History

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sequence A (Type: EXPERIMENTAL): cross-over
- Sequence B (Type: EXPERIMENTAL): cross-over

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 25 years of age, generally healthy~* Habitual calcium intake below 600mg/d~* Overweight or obese (BMI between 24 and 35kg/m2, refer to the Chinese standard)~* Stable body weight (body weight change less than 1kg two months before screening)~* Less than 3 times of 20min of physical exercise per week~* Signed written informed consent~Exclusion Criteria:~* Coronary heart disease, hypertension, diabetes; hepatic insufficiency or renal insufficiency, hyper- or hypothyroidism, mal-absorption, cholesterol concentrations requiring pharmaceutical treatment~* Pregnant or lactating woman~* Use of calcium supplements, oral antidiabetic agents, antihyperlipidemics or any other medications affecting metabolism 30 days before randomization~* Participating in another weight loss programs (i.e. taking oral pharmacotherapeutic agents and/or herbal preparations intended for the management of obesity; excessive physical activity; be on a diet)~* On special diets (i.e. vegetarian)~* Presently taking or have recently taken a prescription drug such as fluoroquinolone antibiotics, tetracycline, or levothyroxine (thyroid medication)~* Participating in another clinical trial 6 months before randomization~* Unlikely to be compliant (i.e. alcohol, drug abuse)~* Refusal or inability to give informed consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Calcium+D (Type: EXPERIMENTAL): Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
- Control (Type: PLACEBO_COMPARATOR): A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.~* Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.~Exclusion Criteria:~* Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:~* Inflammatory breast cancer~* Histologically positive supraclavicular nodes~* Ulceration/infiltration of local skin metastasis~* Neoadjuvant chemotherapy~* Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion~* ER and PR negative primary tumor or ER/PR unknown status.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exemestane (Type: EXPERIMENTAL): None
- tamoxifen + exemestane (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female patients 18 years of age or older~2. Diagnosis of ESRD \[Glomerular Filtration Rate (GFR) ≤ 15 mL/min\]~3. CAPD using only Dianeal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time~4. Diabetes Mellitus (Type 1 and 2)~5. HbA1c \> 6.0% but ≤ 12.0%~6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL~7. Total Kt/V ≥ 1.7~Exclusion Criteria:~1. Blood Urea Nitrogen (BUN) \> 95 mg/dL~2. Exposure to Extraneal within 60 days of Screening~3. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP \< 77mm Hg) at Screening~4. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days~5. Cardiovascular event within the last 30 days~6. Ongoing clinically significant congestive heart failure \[New York Heart Association (NYHA) class III or IV\]~7. Allergy to starch-based polymers, glycogen storage disease or isomaltose/maltose intolerance~8. Receiving rosiglitazone maleate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-glucose Sparing (Type: ACTIVE_COMPARATOR): Dianeal only
- Glucose Sparing (Type: EXPERIMENTAL): Dianeal, Extraneal, Nutrineal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete